Mark R Toshner

List of Publications by Year
in descending order

117	15,536	53751 45	22147 113
papers	citations	h-index	g-index

128	128	128	25179
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119.	13.7	1,041
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
4	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature, 2022, 603, 706-714.	13.7	756
5	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature, 2021, 596, 417-422.	13.7	549
6	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
7	Single-cell multi-omics analysis of the immune response in COVID-19. Nature Medicine, 2021, 27, 904-916.	15.2	452
8	Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. ELife, 2020, 9, .	2.8	423
9	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine,the, 2021, 9, 1275-1287.	5.2	394
10	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. American Journal of Human Genetics, 2017, 100, 75-90.	2.6	343
11	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	13.7	338
12	Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1171-1177.	2.5	331
13	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy. Circulation, 2016, 133, 1761-1771.	1.6	307
14	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	5.8	279
15	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2021, 397, 605-612.	6.3	234
16	Longitudinal analysis reveals that delayed bystander CD8+ TÂcell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity, 2021, 54, 1257-1275.e8.	6.6	230
17	Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2008, 134, 229-236.	0.4	226
18	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	6.3	214

#	Article	IF	Citations
19	Evidence of Dysfunction of Endothelial Progenitors in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 780-787.	2.5	206
20	Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. European Respiratory Journal, 2014, 44, 1635-1645.	3.1	205
21	The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities. Thorax, 2016, 71, 462-473.	2.7	169
22	Neutrophil Extracellular Traps Promote Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2078-2087.	1.1	158
23	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. Circulation, 2017, 135, 460-475.	1.6	154
24	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 2020, 583, 90-95.	13.7	148
25	HIF2Î±â€“arginase axis is essential for the development of pulmonary hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8801-8806.	3.3	140
26	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	5.2	122
27	Bone Morphogenetic Protein Receptor Type II Deficiency and Increased Inflammatory Cytokine Production. A Gateway to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 859-872.	2.5	113
28	Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033.	1.6	111
29	Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension. Circulation, 2012, 126, 1099-1109.	1.6	99
30	The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. Human Molecular Genetics, 2013, 22, 3667-3679.	1.4	86
31	Fibrinogen AÂ Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2008, 31, 736-741.	3.1	83
32	Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax, 2011, 66, 326-332.	2.7	82
33	A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Haemostasis, 2020, 18, 114-122.	1.9	81
34	Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	2.5	80
35	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	5.8	80
36	Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H259-H264.	1.5	78

#	Article	IF	Citations
37	Clinical trial protocol for TRANSFORMâ€UK: A therapeutic openâ€label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-8.	0.8	67
38	Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2018, 11, e002087.	1.6	62
39	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. Cell Reports Medicine, 2020, 1, 100099.	3.3	61
40	Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. ELife, 2021, 10, .	2.8	57
41	A Practical and Efficient Cellular Substrate for the Generation of Induced Pluripotent Stem Cells from Adults: Blood-Derived Endothelial Progenitor Cells. Stem Cells Translational Medicine, 2012, 1, 855-865.	1.6	54
42	Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience. Open Heart, 2020, 7, e001144.	0.9	54
43	Transcript Analysis Reveals a Specific HOX Signature Associated with Positional Identity of Human Endothelial Cells. PLoS ONE, 2014, 9, e91334.	1.1	53
44	Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood. Journal of Visualized Experiments, 2015, , e53384.	0.2	53
45	Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients. Mayo Clinic Proceedings, 2021, 96, 2587-2597.	1.4	51
46	Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2007, 101, 2254-2262.	1.3	50
47	Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. Cell Reports Medicine, 2020, 1, 100062.	3.3	47
48	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18.	2.6	46
49	Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia. American Journal of Human Genetics, 2019, 104, 948-956.	2.6	45
50	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594.	2.5	45
51	Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. Thorax, 2007, 62, 617-622.	2.7	43
52	Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19. ELife, 2020, 9, .	2.8	40
53	Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH. European Respiratory Journal, 2012, 40, 612-617.	3.1	38
54	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics, 2018, 103, 144-153.	2.6	36

#	Article	IF	Citations
55	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. Journal of Heart and Lung Transplantation, 2021, 40, 1301-1326.	0.3	36
56	Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Vascular Pharmacology, 2007, 46, 449-455.	1.0	35
57	Tricuspid regurgitation and the right ventricle in risk stratification and timing of intervention. Echo Research and Practice, 2019, 6, R26-R40.	0.6	35
58	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1102-1111.	2.5	35
59	The ADAMTS13â€“VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801805.	3.1	31
60	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. European Respiratory Journal, 2019, 53, 1801429.	3.1	31
61	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463.	3.1	31
62	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax, 2017, 72, 1035-1045.	2.7	30
63	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	1.6	29
64	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. European Respiratory Journal, 2021, 57, 2000124.	3.1	29
65	CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2020, 56, 1902096.	3.1	28
66	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. American Journal of Human Genetics, 2017, 100, 334-342.	2.6	26
67	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2003201.	3.1	25
68	The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease. Physiological Reports, 2015, 3, e12363.	0.7	24
69	Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2^{+/â^'} Mice with Schistosomiasis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1355-1365.	2.5	23
70	Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801787.	3.1	23
71	Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment. Journal of Heart and Lung Transplantation, 2021, 40, 1223-1234.	0.3	23
72	Pulmonary hypertension: advances in pathogenesis and treatment. British Medical Bulletin, 2010, 94, 21-32.	2.7	21

#	Article	IF	Citations
73	IL-6 in pulmonary hypertension: why novel is not always best. European Respiratory Journal, 2020, 55, 2000314.	3.1	21
74	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 2021, 12, 7104.	5.8	21
75	NT-proBNP Does Not Rise on Acute Ascent to High Altitude. High Altitude Medicine and Biology, 2008, 9, 307-310.	0.5	20
76	Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. Cardiovascular Research, 2021, 117, 2309-2325.	1.8	20
77	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460.	2.5	19
78	Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2010, 29, 610-615.	0.3	18
79	Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. Thorax, 2022, 77, 717-720.	2.7	16
80	Endothelial progenitor cells in pulmonary hypertension Ã¢Â€Â“ dawn of cell-based therapy?. International Journal of Clinical Practice, 2010, 64, 7-12.	0.8	15
81	Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment. F1000prime Reports, 2014, 6, 38.	5.9	15
82	The impact of hypoxia on B cells in COVID-19. EBioMedicine, 2022, 77, 103878.	2.7	15
83	Logâ€Transformation Improves the Prognostic Value of Serial NTâ€proBNP Levels in Apparently Stable Pulmonary Arterial Hypertension. Pulmonary Circulation, 2011, 1, 244-249.	0.8	13
84	Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. Life Sciences, 2014, 118, 391-396.	2.0	13
85	Age should not be a barrier for pulmonary endarterectomy in carefully selected patients. European Respiratory Journal, 2017, 50, 1701804.	3.1	12
86	The outcome of reoperative pulmonary endarterectomy surgery. Interactive Cardiovascular and Thoracic Surgery, 2018, 26, 932-937.	0.5	11
87	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. BMJ Open, 2020, 10, e044566.	0.8	11
88	Arrhythmic Burden and Outcomes in Pulmonary Arterial Hypertension. Frontiers in Medicine, 2019, 6, 169.	1.2	10
89	Repurposing of medications for pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-12.	0.8	10
90	Vascular Thrombosis in Severe COVID-19 Requiring Extracorporeal Membrane Oxygenation: A Multicenter Study. Critical Care Medicine, 2022, 50, 624-632.	0.4	9

#	Article	IF	Citations
91	Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 81-93.	2.5	9
92	Current differences in referral patterns for pulmonary endarterectomy in the UK. European Respiratory Journal, 2008, 32, 660-663.	3.1	8
93	The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. European Respiratory Journal, 2017, 50, 1701141.	3.1	8
94	Risk of Potentially Life-Threatening Thyroid Dysfunction Due to Amiodarone in Idiopathic Pulmonary Arterial Hypertension Patients. Journal of the American College of Cardiology, 2011, 57, 997-998.	1.2	7
95	Rising COVID-19 related acute pulmonary emboli but falling national CTEPH referrals from a large national dataset. ERJ Open Research, 2021, 7, 00431-2021.	1.1	7
96	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. IScience, 2022, 25, 103971.	1.9	7
97	Hematopoietic stem cell transplantation alters susceptibility to pulmonary hypertension in Bmpr2â€deficient mice. Pulmonary Circulation, 2018, 8, 1-9.	0.8	6
98	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and singleâ€arm efficacy. Pulmonary Circulation, 2021, 11, 1-12.	0.8	5
99	Myeloid angiogenic cells exhibit impaired migration, reduced expression of endothelial markers, and increased apoptosis in idiopathic pulmonary arterial hypertension. Canadian Journal of Physiology and Pharmacology, 2019, 97, 306-312.	0.7	4
100	BMP9 Morphs into a Potential Player in Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 819-821.	2.5	4
101	A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-9.	0.8	4
102	The fibrocyte in pulmonary hypertension: we seek him here, we seek him there. European Respiratory Journal, 2012, 39, 5-6.	3.1	3
103	Chronic thromboembolic pulmonary hypertension following longâ€term peripherally inserted central venous catheter use. Pulmonary Circulation, 2019, 9, 1-3.	0.8	3
104	Response to letter to the Editor: Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Haemostasis, 2020, 18, 756-757.	1.9	3
105	Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom. Clinical Trials, 2021, 18, 615-621.	0.7	3
106	CASPA (CArdiac Sarcoidosis in PApworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study. BMJ Open Respiratory Research, 2020, 7, e000608.	1.2	3
107	Genetic testing in pulmonary hypertension: how should our clinical practice reflect recent advances?. European Respiratory Journal, 2016, 47, 388-389.	3.1	2
108	Analyses of blood outgrowth endothelial cells reveal an endothelial HOX gene signature in human beings. Lancet, The, 2013, 381, S108.	6.3	1

#	Article	IF	Citations
109	Reply to â€œLetter to the editor: â€˜Pulsatile pulmonary artery pressure: are fluid-filled catheters accurate in pulmonary hypertension?'â€• American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H1682-H1682.	1.5	1
110	Increased Antielastase Activity in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 652-655.	1.4	1
111	Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?. European Respiratory Journal, 2020, 56, 1902334.	3.1	1
112	The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension. Chronic Respiratory Disease, 2022, 19, 147997312210784.	1.0	1
113	Prevalence and clinical significance of conduction disease in patients with idiopathic pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 861-865.	0.3	1
114	Treatment options in pulmonary arterial hypertension. Future Prescriber, 2007, 8, 5-8.	0.1	0
115	CIPHER AND CIPHER-MRI: TWO PROSPECTIVE, MULTICENTER STUDIES FOR THE IDENTIFICATION OF BIOMARKER SIGNATURES FOR EARLY DETECTION OF PULMONARY HYPERTENSION. Chest, 2020, 158, A2191-A2193.	0.4	0
116	Response to: Direct oral anticoagulants: Still too early for prime time after pulmonary endarterectomy?. Journal of Thrombosis and Haemostasis, 2020, 18, 759-761.	1.9	0
117	Abstract 202: The Role of Neutrophil Extracellular Traps in the Pathogenesis of Pulmonary Hypertension.. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0